The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.675
Bid: 0.65
Ask: 0.70
Change: -0.04 (-5.59%)
Spread: 0.05 (7.692%)
Open: 0.675
High: 0.675
Low: 0.675
Prev. Close: 0.675
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Centamin Falls After Gold Production Drops

Mon, 09th Jul 2018 10:08

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------Just Eat, up 2.4%. RBC Capital raised the online takeaway platform to its Top Pick list.BHP Billiton, up 1.8%. Shares in the Anglo-Australian miner were higher after Reuters reported on Friday that oil major BP is in the lead to acquire the US onshore shale oil and gas assets from BHP after submitting an offer over USD10 billion. BP was down 1.0%.----------FTSE 100 - LOSERS----------Hargreaves Lansdown, down 0.9%. JPMorgan downgraded the funds supermarket to Underweight from Neutral. ----------FTSE 250 - WINNERS----------Stobart Group, up 4.8%. The support services firm said on Saturday that its former chief executive had been re-elected and then immediately dismissed. A majority of shareholders, 51%, voted Andrew Tinkler back onto the board at the company's annual general meeting on Friday, the results of which were delayed until Saturday evening. Tinkler's re-election and his subsequent dismissal were announced within Stobart's Saturday AGM results. In its Saturday statement, Stobart noted that Tinkler's election was passed by the required majority but justified its decision to remove him from the board once again. Tinkler stepped down as chief executive last year but remained on the board. He was removed altogether after accusations of "subverting the company for his own interests" and attempting to cash GBP30 million worth of shares, the Daily Mail said.TalkTalk Telecom Group, up 3.5%. JPMorgan raised the home phone and broadband provider to Neutral from Underweight. ----------FTSE 250 - LOSERS----------Centamin, down 7.5%. The gold miner said second quarter gold production from its Sukari mine in Egypt dropped 25% as underground grades fell below forecast. For the three months to June 30, the miner produced 92,803 ounces of gold compared to 124,641 in the comparative year ago period. In the six months to June 30, production fell 7% to 217,099 ounces form 233,828 ounces year-on-year. In May, the company revised its annual production guidance of between 505,000 and 515,000 ounces at a cash cost of production of USD625 to USD640 per ounce produced and an all-in sustaining cost of USD875 to USD890 per ounce sold. "We have experienced several challenges this year, resulting in the revision of our full year guidance in May," said Chief Executive Officer Andrew Pardey.----------OTHER MAIN MARKET AND AIM - WINNERS----------Legendary Investments, up 17%. The investment company recorded double digit growth in investments and net assets in its recently-ended financial year. In the year to the end of March, the company invested GBP6.2 million versus GBP4.3 million the year before. Net assets saw a 28% increase to GBP6.0 million from GBP4.7 million. During the year, one of Legendary's holdings, Virtualstock Holdings received an investment of GBP4.5 million from European venture capital firm Notion Capital. Legendary holds GBP66 million worth of stake in Virtualstock. In addition, Legendary converted its shares in its Kyrgyz gold asset to shares in Circle Oil Tunisia in December 2017, following Circle Oil Tunisia's acquisition by Dunraven Resources, meaning the the company now holds a 2.0% stake in Dunraven.----------OTHER MAIN MARKET AND AIM - LOSERS----------N4 Pharma, down 52%. The drug reformulation company said that its sildenafil reformulation clinical trial has not met its key target endpoints. The company said that the product formulation will need to be reviewed to assess what changed need to be made to make the reformulated drug viable to N4 Pharma's patent position. "This part of the process of drug reformulation is always going to be a challenge and whilst this preliminary data is clearly disappointing, we will need to see the full set of results expected around the end of August to understand the detailed implications for the formulation," said Chief Executive Officer Nigel Theobald.----------
More News
25 Mar 2020 12:15

N4 Pharma Explores Nuvec's Potential In Covid-19 Vaccine Delivery

N4 Pharma Explores Nuvec's Potential In Covid-19 Vaccine Delivery

Read more
24 Mar 2020 15:49

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
25 Feb 2020 11:42

N4 Pharma Annual Loss Narrows Amid Work To Improve Nuvec System

N4 Pharma Annual Loss Narrows Amid Work To Improve Nuvec System

Read more
25 Feb 2020 08:49

N4 Pharma narrows loss as it continues development work

(Sharecast News) - Specialist pharmaceutical company N4 Pharma reported a smaller operating loss for 2019 on Tuesday, at ?0.95m, compared to ?1.42m in the prior year.

Read more
11 Feb 2020 14:19

N4 Pharma shares rise on partnership with Nanomerics

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has signed a 14-month research collaboration with Nanomerics to produce and test two candidate formulations using its 'Nuvec' delivery system, it announced on Tuesday.

Read more
11 Feb 2020 11:37

N4 Pharma Signs Research Collaboration Agreement With Nanomerics

N4 Pharma Signs Research Collaboration Agreement With Nanomerics

Read more
18 Sep 2019 12:04

N4 Pharma Interim Loss Widens After Non-Repeat Of Grant, Disposal Gain

(Alliance News) - N4 Pharma PLC on Wednesday said its loss widened slightly in the first half of the year, owing to grant income and a gain on an investment sale the year before which did not in a

Read more
20 Aug 2019 11:49

N4 Pharma Repeats Study And Finds Nuvec Successful At "Certain Doses"

(Alliance News) - N4 Pharma PLC on Tuesday said it has repeated the in-vivo study of Nuvec and shown it does work "when using multiple injections at certain doses".Shares in N4 at

Read more
19 Jun 2019 13:38

N4 Pharma To Start Experiments On Nuvec; Results Due In Two Months

(Alliance News) - N4 Pharma PLC on Wednesday said it will begin experiments on its Nuvec system on Friday this week with results due in around two months.Shares in N4 were up 20% at 4.30 in

Read more
12 Jun 2019 16:04

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 13 JuneTescoWM Morrison SupermarketsSirius MineralsJust Jack 14 Evans 17 18

Read more
21 May 2019 13:25

N4 Pharma Appoints John Chiplin as Non-Executive Chairman

LONDON (Alliance News) - N4 Pharma PLC on Tuesday said it appointed John Chiplin as non-executive chair of the company with immediate effect.Furthermore, the pharmaceutical firm appointed a

Read more
14 May 2019 12:09

N4 Pharma Loss Narrowed By Cost; Will Explore Assets Outside Nuvec

LONDON (Alliance News) - N4 Pharma PLC on Tuesday reported a narrowed loss for 2018 on lower costs and said it is exploring new opportunities while continuing work on core Nuvec drug delivery in -

Read more
15 Apr 2019 15:33

N4 Pharma reassures shareholders over future of 'Nuvec'

(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated the market on the development of 'Nuvec' on Monday, following the disclosure of inconsistencies in the efficacy of Nuvec between various in vitro and in vivo studies.

Read more
15 Apr 2019 15:20

N4 Pharma Finds Issues With In Vivo Nuvec Testing And Plans Repeat

LONDON (Alliance News) - N4 Pharma PLC on Monday said it has become aware of a number of issues with the in vivo studies of its Nuvec delivery system.On Tuesday last week, N4 announced of a

Read more
9 Apr 2019 11:27

N4 Pharma Shares Sink As Nuvec Fails To Produce Response In-Vivo

LONDON (Alliance News) - N4 Pharma PLC on Tuesday said early in-vivo tests of its Nuvec delivery system did not match positive results from in-vitro tests, causing shares to slump.Shares in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.